In a 15-month longitudinal clinical trial*, patients who were receiving tirzepatide were significantly more likely to achieve weight loss, and their changes in weight were larger at 3 months, 6 months, and 12 months in comparison to patients taking semaglutide
GLP-1R/GIPR GLP-1R (glucagon-like peptide-1 receptor) is a Class B G-protein-coupled receptor (GPCR) expressed in various tissues and organs, including pancreatic -cells, the stomach, small intestine, heart, kidneys, lungs, and brain
To understand the durability and stability of weight outcomes after stopping GLP-1s, we studied 188,722 patients who stopped using a GLP-1 medication after being on it for at least 90 days and who lost at least 5 pounds while on it
tirzepatide 4813.45 Da Conclusion# Tirzepatide and retatrutide represent successive generations of incretin-based therapeutics
Carnitine kinetics during dialysis